Takeda’s TAK-875 Could Take On Other Oral Antidiabetics, Early Data Suggest
This article was originally published in PharmAsia News
Executive Summary
Takeda’s novel GPR40 agonist TAK-875 has proven in Phase II to have blood sugar lowering on par with widely prescribed sulfonylureas, without causing hypoglycemia, and now moves into Phase III.
You may also be interested in...
Proliferation Of New Diabetes Drugs Prompts Call For Comparative Effectiveness Trials
Presenter at ADA meeting warns against "alarmist" reaction to imbalance in cancer rates for Bristol's SGLT-2 inhibitor dapagliflozin.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.